Senti Biosciences Third Quarter 2023 Earnings EPS Beats Expectations, Revenues Lag - Simply Wall St
SNTI Stock | USD 2.18 0.01 0.46% |
Under 54% of Senti Biosciences' investor base is interested to short. The analysis of the overall investor sentiment regarding Senti Biosciences suggests that many traders are impartial. Senti Biosciences' investing sentiment shows overall attitude of investors towards Senti Biosciences.
Senti |
Senti Biosciences Third Quarter 2023 Earnings EPS Beats Expectations, Revenues Lag Simply Wall St
Read at news.google.com
Senti Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Senti Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Senti Biosciences Fundamental Analysis
We analyze Senti Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Senti Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Senti Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Senti Biosciences is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Senti Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Senti Biosciences stock to make a market-neutral strategy. Peer analysis of Senti Biosciences could also be used in its relative valuation, which is a method of valuing Senti Biosciences by comparing valuation metrics with similar companies.
Peers
Senti Biosciences Related Equities
LIPO | Lipella Pharmaceuticals | 12.55 | ||||
FENC | Fennec Pharmaceuticals | 6.39 | ||||
RAPT | RAPT Therapeutics | 3.70 | ||||
TYRA | Tyra Biosciences | 2.21 | ||||
QNRX | Quoin Pharmaceuticals | 1.69 | ||||
MLYS | Mineralys Therapeutics, | 1.68 | ||||
FHTX | Foghorn Therapeutics | 0.77 | ||||
CING | Cingulate | 0.42 | ||||
XLO | Xilio Development | 1.12 | ||||
CNTB | Connect Biopharma | 2.00 | ||||
SABS | SAB Biotherapeutics | 3.19 | ||||
MNPR | Monopar Therapeutics | 3.48 | ||||
CVKD | Cadrenal Therapeutics, | 9.54 |
Complementary Tools for Senti Stock analysis
When running Senti Biosciences' price analysis, check to measure Senti Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senti Biosciences is operating at the current time. Most of Senti Biosciences' value examination focuses on studying past and present price action to predict the probability of Senti Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senti Biosciences' price. Additionally, you may evaluate how the addition of Senti Biosciences to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |